Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia

British Journal of Haematology
Thomas PabstBeatrice U Mueller

Abstract

The transcription factor CEBPA is crucial for normal myeloid differentiation. CEBPA gene mutations have been reported in patients with acute myeloid leukaemia. The inevitable evolution of chronic myeloid leukaemia (CML) in chronic phase (CP) to a fatal blast crisis (BC) is assumed to result from the acquisition of additional genetic changes in the leukaemic clone. Gain of CEBPA mutations might represent a key event causing the differentiation block observed in myeloid CML-BC, but not in CML-CP. Here, no CEBPA mutation in 95 CML-BC patients was found, suggesting a limited role, if any, of CEBPA mutations in this disorder.

References

Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E FeinsteinE Canaani
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·D E ZhangD G Tenen
Dec 26, 2001·Nature Genetics·Danilo PerrottiBruno Calabretta
Feb 4, 2003·Nature Reviews. Cancer·Daniel G Tenen
Jan 1, 2004·Molecular and Cellular Biology·Sarah E RossOrmond A MacDougald
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Daniel HelblingThomas Pabst

❮ Previous
Next ❯

Citations

May 25, 2007·Nature Reviews. Cancer·Junia V Melo, David J Barnes
Oct 16, 2007·Oncogene·T Pabst, B U Mueller
Jul 2, 2010·The Journal of Clinical Investigation·Danilo PerrottiTomasz Skorski
Jun 3, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A K TrivediS M Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved